ABL genomic editing sufficiently abolishes oncogenesis of human chronic myeloid leukemia cells in vitro and in vivo

Medicine and Dentistry

• In Vitro 100%
• Carcinogenesis 100%
• Chronic Myelogenous Leukemia 100%
• Leukemia Cell 100%
• K562 Cells 25%
• Imatinib 25%
• Indel Mutation 25%
• Leukemia 25%
• Protein Expression 12%
• Cancer Cell 12%
• Programmed Cell Death 12%
• Cell Death 12%
• Cell Growth 12%
• Oncoprotein 12%
• Infection 12%
• Cancer Growth 12%
• Combination Therapy 12%
• Phosphotransferase Inhibitor 12%
• Cell Survival 12%
• Cell Population 12%
• Bioluminescence 12%
• Carcinogenicity 12%
• Xenograft 12%
• Spontaneous Remission 12%
• BCR ABL Protein 12%
• Philadelphia 1 Chromosome 12%
• Cas9 12%
• Clustered Regularly Interspaced Short Palindromic Repeat 12%
• Bone Marrow Cell 12%

Biochemistry, Genetics and Molecular Biology

• Myeloid 100%
• ABL (Gene) 100%
• Carcinogenesis 100%
• Mouse 42%
• Cancer Cell 28%
• Imatinib 28%
• Indel 28%
• Genome Editing 28%
• Cell Growth 28%
• K562 Cells 28%
• Protein Expression 14%
• Mouse Model 14%
• Cell Survival 14%
• Bioluminescence Imaging 14%
• CRISPR/Cas9 14%
• Philadelphia Chromosome 14%
• Kinase 14%
• Phosphotransferase 14%
• Cell Death 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Myeloid Leukemia 100%
• Carcinogenesis 100%
• Mouse 37%
• Leukemia 37%
• Imatinib 25%
• Malignant Neoplasm 12%
• Infection 12%
• Mouse Model 12%
• Oncoprotein 12%
• Phosphotransferase Inhibitor 12%
• Cancer Growth 12%
• Carcinogenicity 12%
• Remission 12%
• BCR ABL Protein 12%
• Philadelphia 1 Chromosome 12%
• Combination Therapy 12%